TITAN PHARMACEUTICALS INC Logo

TITAN PHARMACEUTICALS INC

Develops a long-term drug delivery implant for treating chronic central nervous system disorders.

TTNP | US

Overview

Corporate Details

ISIN(s):
US8883146065
LEI:
Country:
United States of America
Address:
400 OYSTER POINT BLVD, 94080 SAN FRANCISCO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Titan Pharmaceuticals, Inc. is a development-stage biopharmaceutical company that develops proprietary therapeutics for the treatment of select chronic diseases. The company's core technology is its clinically proven ProNeura® platform, a long-term, continuous drug delivery system. This platform is designed to deliver stable, non-fluctuating levels of medication for periods of up to one year from a single subcutaneous implant. Titan's research and development activities are focused on exploring new therapeutic applications for the ProNeura platform, with a primary emphasis on treating central nervous system disorders. In late 2023, the company announced a merger with Black Titan Corporation.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all TITAN PHARMACEUTICALS INC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for TITAN PHARMACEUTICALS INC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for TITAN PHARMACEUTICALS INC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Summit Therapeutics Inc. Logo
Advancing a Phase 3 bispecific antibody for lung cancer and other solid tumors.
United States of America
SMMT
SunBio, Inc. Logo
Develops biopharmaceuticals and devices like artificial blood using proprietary PEGylation technology.
South Korea
067370
Sunshine Biopharma Inc. Logo
Develops novel oncology/antiviral drugs and commercializes generic pharmaceuticals in Canada.
United States of America
SBFM
SUPERNUS PHARMACEUTICALS, INC. Logo
Develops and commercializes therapies for CNS diseases like epilepsy, migraine, and ADHD.
United States of America
SUPN
SURMODICS INC Logo
Provides medical device coatings, vascular products, and components for diagnostic tests.
United States of America
SRDX
SUTRO BIOPHARMA, INC. Logo
Develops engineered cancer drugs like ADCs using a cell-free protein synthesis platform.
United States of America
STRO
Swedencare AB (publ) Logo
Develops and markets premium health supplements and pharmaceuticals for cats, dogs, and horses.
Sweden
SECARE
Swedish Orphan Biovitrum Logo
Develops innovative therapies for rare diseases in haematology, immunology, and specialty care.
Sweden
SOBI
SymBio Pharmaceuticals Limited Logo
Acquires and commercializes specialty drugs for unmet needs in Japan and the Asia-Pacific region.
Japan
4582
SynAct Pharma Logo
Biotech developing oral therapies to resolve inflammation in diseases like rheumatoid arthritis.
Sweden
SYNACT

Talk to a Data Expert

Have a question? We'll get back to you promptly.